Several plant hormones function as natural modulators of protein-protein interactions (PPIs) and ultimately modulate the affinity of hormone receptors for their protein binding partners 1,2 .
5 tunnels adjacent to ABA's 3-CH and 4'-C=O (Supplementary Results, Supplementary Fig.   1a,b) . The entrance to these tunnels (referred to as 3-and 4'-tunnels) lay on the interface that normally contacted PP2C. The 3 tunnel was a relatively simple cleft formed by five highly conserved hydrophobic residues (in PYR1: Phe61, Leu87, Pro88, Phe159 and Val163; Supplementary Fig. 1c-f) . Because some 3-modified analogs of ABA retained activity (Supplementary Table 1 ) 36, 38 , it was reasoned that the 3 tunnel might have accepted alkyl substituents at the 3 position that could then form hydrophobic contacts with the tunnel. One might have expected such derivatives to potentially stabilize the gate-closed conformer, interfere with gate closure or, in the case of longer chains, protrude through the tunnel and prevent PP2C binding. Thus, alterations of chain length could conceivably have resulted in both agonists and antagonists, making this an interesting site for ABA modifications.
On the basis of the above considerations, 3-alkylsulfanyl ABAs (3-13) were designed by nucleophilic addition of alkyl thiolate to the 2,3-epoxides 2, prepared from ABA (1; Fig.   1a ). For simplicity, these are called the ASn compound series, where n denotes the alkyl chain length. Before preparing these compounds, a model of a PYR1-AS6 complex was constructed on the basis of crystal structures of PYR1-ABA complexes 17, 18 . This model suggested that a hexyl chain was of sufficient length to protrude through the PYR1 surface ( Supplementary Fig.   3a ) and occupy a position normally occupied by the highly conserved PP2C residue Val393 (HAB1 numbering; Supplementary Fig. 3b ). Therefore, AS6 was predicted to bind PYR1's ligand-binding pocket and disrupt PP2C binding. These analyses also suggested that compounds with n < 4 might stabilize gate closure and act as agonists. The validity of these predictions was established by the synthesis and characterization of 11 ASn compounds (n = 2-12; Fig. 1a ).
7 series contained both agonist and antagonist activities with good bioavailabilities and activities beyond the model plant.
The molecular bases of AS2, AS4 and AS6 actions in vivo were further characterized in
Arabidopsis. AS2 was found to induce expression of ABA-responsive genes and the -glucuronidase (GUS) gene on an ABA-responsive, transcriptional, reporter line with slightly stronger activity than ABA, which was consistent with the seed germination data (Fig. 2a,b) .
With AS4, clear expression of ABA-responsive genes was not observed by qRT-PCR, but weak reporter gene activation was detected in root tissues (Fig. 2a,b) . As expected, AS6 was not able to induce obvious ABA responses, as measured by both qRT-PCR gene expression and reporter line assays (Fig. 2a,b) . AS2 enhanced expression of ABA-inducible genes, whereas AS4 and AS6 lessened their expression in cotreatment with ABA ( Fig. 2c,d ). This antagonist effect was stronger for AS6 than AS4, the latter only partially decreasing expression of these genes.
Notably, AS6 also repressed expression of stress-induced ABA-responsive genes in response to treatment with mannitol, which induced ABA synthesis by mimicking the water loss caused by drought ( Supplementary Fig. 10 ). These physiological data suggested that AS2 and AS6 functioned as a PYL agonist and antagonist, respectively, whereas AS4 exhibited an intermediate effect, consistent with predictions based on the present PYR1-AS6 model ( Supplementary Fig. 3 ).
PyrA is a synthetic PYL agonist but not an ABA analog and inhibits seed germination primarily by activating PYR1 (ref. 24) . Additionally, it has weak antagonist activity in assays with PYL2 in vitro, which perhaps explains its inability to trigger a strong ABA response in adult plant tissues. Given this, the two compounds were compared, and, consistent with previous reports 24, 35 , PyrA was observed not to induce strong ABA responses in vegetative tissues. More notably, PyrA, unlike AS6, did not block induction of ABA-inducible genes by either exogenous ABA treatment or endogenous stimulation by mannitol treatment (Fig. 2c,d 8 and Supplementary Fig. 10 ). Therefore, the previously reported PYL2-selective antagonist activity of PyrA 14 seemed not to be physiologically relevant, and, notably, the reported activity required a high molar excess of PyrA relative to ABA in vitro to be observed.
Biochemical characterization of ASn
The 3 tunnel is enclosed by highly conserved residues, and therefore it was expected that ASn compounds might have broad-spectrum activity across the receptor family. Thus, the effects of ASns on 11 of the 13 Arabidopsis receptors were examined using phosphatase assays (PYL7 and PYL12 have remained recalcitrant to expression as active proteins in our hands). In these assays, receptor activation was monitored by PP2C activity inhibition, and effective agonists exhibited near-complete PP2C activity inhibition at saturating concentrations, whereas partial agonists failed to completely inhibit PP2C activity. AS2 activated dimeric receptors (PYR1 and PYL1-3) with potencies comparable to that of ABA ( Fig. 3a) and showed incomplete activation of the monomeric receptors PYL4, PYL5 and PYL11; thus, AS2 was not a broad-spectrum agonist. The recently reported agonist quinabactin also primarily activates dimeric receptors, and the AS2 effects observed here provided independent evidence for the sufficiency of dimeric receptors to activate ABA responses 34 . AS4 displayed incomplete activation of dimeric receptors compared to ABA, and AS6 was also able to partially cause activation. Although AS6 bound to PYLs with affinity comparable to ABA, as described below, its effects included less than 50% PP2C inhibition, which suggested that AS6 acted as a weak partial agonist.
The antagonist activities of these compounds in vitro were characterized by examining their ability to reverse ABA-mediated PP2C inhibition. These experiments showed that AS4 and AS6 antagonized ABA-dependent PP2C inhibition for all of the receptors tested, indicating broad-spectrum antagonist activity ( Fig. 3 and Supplementary Fig. 11 ). AS6's effects were greater than those of AS4, but neither enabled full recovery of PP2C activity, even when present at a 20-fold excess over ABA. This might be explained by the intrinsic partial-agonist activity of AS6 and, thus, in the presence of ABA, AS6 only enabled PP2C activity recovery to ~50% of the inhibition observed in the presence of AS6 alone.
The mechanism of AS6 antagonist activity was further characterized by pulldown assays in vitro using recombinant PYLs in combination with HAB1. In cotreatment experiments, AS6 blocked ABA-induced PYL-PP2C interactions in a dose-dependent manner ( Supplementary Fig. 11 ), as expected for an antagonist. AS6 did not block ABA-independent interactions of PYL6, PYL8 and PYL10 with HAB1 but did reduce their ABA-dependent interactions ( Supplementary Fig. 11 ). These biochemical data showed that AS6 acted as an antagonist by blocking ABA-induced PYL-PP2C interactions.
Thermodynamic and structural analysis of PYL-AS6 complexes
Isothermal titration calorimetry was next used to characterize AS6 binding with monomeric receptors, which were selected over dimeric receptors because they display simple ligand association and dissociation and lack a dimer dissociation step. These analyses revealed apparent dissociation constants (Kd) of 0.48 ± 0.10 M (s.e.m.) and 1.28 ± 0.72 M (PYL5 and PYL10, respectively) with negative enthalpies, indicating an exothermic binding process ( Supplementary Fig. 12 and Supplementary Table 4) . These values were comparable to those of ABA (0.88 ± 0.11 M and 0.78 ± 0.12 M for PYL5 and PYL10, respectively. In comparison to ABA, AS6 binding to PYL5 was associated with larger negative enthalpy and entropy. In contrast, this was not the case for AS6-PYL10 interactions, which suggested that there might have been subtle mechanistic differences in the AS6 gate-closing dynamics for different receptors.
The molecular mechanism of AS6 activity was then clarified by determining the crystal structure of recombinant PYR1 bound to AS6 at 2.3-Å resolution, using molecular replacement and starting from published PYR1-ABA coordinates (Protein Data Bank (PDB) code 3K90; refinement and structure statistics are summarized in Supplementary Table 5 ). The PYR1-AS6 complex was found to resemble very closely that of the PYR1-ABA complex (Fig. 4a) , and AS6's ABA-skeleton resided in almost the same position normally occupied by ABA (Fig.   4b) . Consistent with the present model-based predictions, the gate loop adopted a closed conformation, and the 3 tunnel accommodated the AS6 S-hexyl chain, which also protruded out onto PYR1's PP2C-interaction surface (Fig. 4c,d and Supplementary Fig. 14) . These observations provided direct evidence that AS6 induced the gate-closed conformer and that the S-hexyl chain was positioned to interfere with PP2C binding through steric effects.
The functional selectivity of ASn
The compounds in the ASn series were structurally nearly identical to ABA, with the exception of their 3-alkyl chains. Although direct evidence was developed here for receptor-mediated physiological effects by these compounds, it is conceivable that activity at other ABA binding sites could have contributed to their effects in vivo. Thus, the effects of AS2 and AS6 on two well-characterized, nonreceptor ABA-binding sites were characterized, and, as described above, ASn compounds were not potent inhibitors of ABA catabolic CYP707A enzymes. Moreover, endogenous ABA concentrations in Arabidopsis seedlings treated with AS2 or AS6 were investigated to examine whether these concentrations were altered by ASn compounds. No significant differences (P  0.1 by one-way analysis of variance; n = 5 or 6) were observed in ABA concentrations between ASn and mock-treated controls ( Supplementary Fig. 15 .6 (also known as AIT1) 44 were described as ABA transporters. The effect of AS6 on AIT1, whose assay system has been established uniquely among the ABA transporters, was examined, and AS6 was found not to substantially inhibit ABA transport activity by AIT1 when present at equimolar concentrations to ABA; however, it weakly inhibited transport when present in tenfold excess ( Supplementary Fig. 16 ). These data suggest that AS6 is not a strong inhibitor of ABA transport activity.
DISCUSSION
A structure-guided design was used to rationally and successfully create an ABA receptor antagonist, demonstrating that this allosteric ligand could be modified relatively easily to yield a PPI inhibitor. Consistent with the present PYR1-AS6 model ( Supplementary Fig. 3 ), the ASn analog series, prepared by 3 S-alkylation of ABA, yielded agonists when n < 4 and yielded antagonists when n > 4. Thus, the 3 position of ABA's ring was found to be a versatile ABA (Affymetrix, Inc., Santa Clara, CA, USA) in the presence or absence of test compounds with gentle shaking at 4 °C for 60 min. The resin was then washed five times with TBS containing 0.025% 2-mercaptoethanol and 10 mM MnCl2, while held on ice. The bound proteins were eluted in 60 l of SDS-sample buffer with 250 mM imidazole and denatured at 95 °C for 5 min.
Then, 10 l of eluate was loaded on a 13% SDS-PAGE gel, and proteins were detected after development by Coomassie brilliant blue staining.
Isothermal titration calorimetry.
ASn-binding studies were performed by isothermal titration calorimetry (ITC) using an iTC200
calorimeter (Microcal, GE Healthcare Bio-Sciences AB) and were conducted at 20 °C and with a solvent of 100 mM phosphate buffer, pH 8.0. His6-tagged PYL5 or His6-tagged PYL10 were assayed at a concentration of 40 M and 50 M, respectively, with AS6 and ABA stock solutions in the injection syringe at tenfold higher concentrations than the proteins. All of the titrations were carried out via a series of 20 injections of 1.25 l each. The data were corrected by subtracting the mixing enthalpies for the AS6 or ABA solutions into protein-free solutions and fitted by Origin for ITC (GE Healthcare Bio-Sciences AB) with a 1/1 binding model.
Protein preparation and crystallization.
For crystallization of the PYR1-AS6 complex, PYR1 was cloned into a pET-28 vector, as previously described 24 . The plasmid was then transformed into E. coli strain BL21-CodonPlus (DE3)-RIPL (Agilent Technologies, Santa Clara, CA, USA), and transformed cells were incubated at 30 °C to an OD600 ~0.5. Protein expression was induced by IPTG addition and incubation at 16 °C for 16 h, after which cells were harvested, frozen, thawed and sonicated.
Protein was then purified from this preparation using a Ni-Sepharose resin (GE Healthcare Bio-Sciences AB) and eluted with binding buffer (150 mM phosphate, pH 8.0, and 300 mM NaCl) supplemented with 250 mM imidazole. The protein was further purified using a Resource Q column (GE Healthcare Bio-Sciences AB) and eluted with binding buffer (10 mM Tris-HCl, pH 8.0) supplemented with 150 mM NaCl. Peak fractions were concentrated using an Amicon Ultrafilter (30,000 MWCO, Millipore Corp., Billerica, MA, USA).
Crystallization was performed using the hanging-drop vapor-diffusion method at 20 °C, and crystallization buffer comprised 100 mM HEPES (pH 7.5) with 20% (v/v) PEG 10,000 as the reservoir buffer. Drops of protein solution (1.5 l, 10 mg ml 1 ) containing 1 mM AS6 were mixed with 1.5 l of reservoir buffer. Crystals were flash-frozen at 100 K under a cold stream of nitrogen gas without cryoprotectant.
Data collection, structure determination and refinement.
Diffraction data of PYR1 cocrystallized with AS6 were collected on beamline 17A at the Photon Factory (Tsukuba, Japan), and data sets were processed with the program HKL2000 (ref.
52). The initial structure of the complex was solved by molecular replacement using the Quantitative analysis of endogenous ABA.
Measurement of endogenous ABA has been described elsewhere 59, 60 . Briefly, 10-d-old plants (0.5-1 g) were incubated for 6 h in a 10 M AS2 or AS6 solution or water as a control . These plants were homogenized in 80% aqueous acetone (v/v) containing 0.1 mg/ml 2,6-di-tert-butyl-4-methylphenol as an antioxidant. A 5.0 ng of [3,5,5,7',7',7'-2 H6]ABA (d6-ABA), as the internal standard, was added to a homogenized sample before the following extraction procedure. The homogenate was centrifuged at 5,000g and 4 °C for 15 min, and the supernatant was reduced to the aqueous phase in vacuo. After washing with hexane, the pH was adjusted to 2 using 0.5 M phosphoric acid, and ABA was extracted into EtOAc. The solvent was removed from this extract in vacuo, and the residue was dissolved in 110 l of 10% MeOH containing 0.1% AcOH (v/v) and introduced into a HPLC. HPLC conditions were as follows: 
Statistical analyses.
All statistical analyses were performed using R version 3.0.2 software, and Grubbs' test was used to detect outliers. Normal distributions and assumptions regarding variance homogeneities in ABA concentrations from each treatment were checked using the Shapiro-Wilk test and Bartlett's test, respectively. Differences in ABA concentrations between treatments were tested using one-way ANOVA.
Transport assay.
ABA transport activities of NPF4.6/AIT1 in a yeast system were determined by directly analyzing ABA taken into cells by LC/MS/MS, as described previously, but with some modifications 42 . Potassium phosphate buffer at pH 5.8, instead of pH 7.5, was used for the assays. ABA was extracted from yeast cells at -30 °C overnight in 1 ml of 80% aqueous acetone containing 1% acetic acid (v/v), with d6-ABA as an internal standard. Supernatants were collected after centrifugation, and acetone was evaporated using a SpeedVac (Thermo Fisher Scientific Inc.) to obtain aqueous extracts containing acetic acid. Solutions were adjusted to 1 ml with 1% acetic acid and applied to Oasis WAX cartridge columns (30 mg, 1 ml; Waters Corp.) prewashed successively with 1 ml of MeCN and methanol, regenerated with 0.5 ml of 0.1 M NaOH and equilibrated with 1 ml of 1% acetic acid. After washing successively with 3-ml volumes of 1% acetic acid and methanol, the fractions containing ABA were eluted with 2 ml of 80% MeCN containing 1% acetic acid (v/v). The eluates were taken to dryness and dissolved in 0.5 ml of chloroform containing 49% ethyl acetate and 1% acetic acid (v/v). They were then loaded on Sep-Pak silica (100 mg; Waters Corp.) cartridge columns prewashed with 3 ml of chloroform and equilibrated with 1 ml of chloroform containing 1% acetic acid.
Fractions containing ABA were eluted with 2 ml of chloroform containing 49% ethyl acetate 
